On Wednesday, Goldman Sachs maintained a Buy rating on Pfizer Inc. (NYSE ... primarily due to strong sales of its COVID-19 treatment, Paxlovid. Despite the positive financial results, Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback